Supplemental Reply to Office Action of June 13, 2007

IN THE CLAIMS

1-10. (Cancelled)

11. (Currently Amended) Process for the preparation of the amorphous form of methyl (S)-(+)-(2-chlorophenyl)-2-(6, 7-dihydro-4*H*-thieno [3,2- c] pyridine-5-yl-acetate hydrogen-sulfate of the formula

which comprises,

dissolving clopidogrel base in a first solvent,

adding sulfuric acid or a mixture of sulfuric acid and the first solvent or a second solvent to the mixture,

adding the obtained mixture containing clopidogrel hydrogensulfate to the <u>a</u> second solvent to obtain a precipitate, and

filtering precipitate,

wherein the first solvent is selected from at least one of the group consisting of: an aprotic solvent that is less polar than the second solvent and a dipolar aprotic solvent, and

Docket No.: 1060-0163PUS1

wherein the second solvent is selected from at least one of the group consisting of: an

Docket No.: 1060-0163PUS1

aprotic solvent, a dipolar aprotic solvent and an apolar solvent

wherein the first solvent and the second solvent are present in one of the following

combinations selected from the group consisting of:

combination (i) acetone and diisopropyl ether;

combination (ii) dichloromethane and diisopropyl ether;

combination (iii) dichloromethane and cyclohexane; and

combination (iv) dichloromethane and ethyl acetate.

12. (Cancelled)

13. (Previously Presented) The process according to claim 11, wherein the method

comprises:

dissolving clopidogrel base in dichloromethane to make a solution,

adding sulfuric acid to the solution,

mixing the solution with cyclohexane to form a precipitate, and

filtering the precipitate.

14. (Previously Presented) The process according to claim 11, which further comprises:

washing the precipitate; and ...

drying the precipitate.

3

MSW/TJS/mua

Application No. 10/562,978 Amendment dated January 30, 2008

Supplemental Reply to Office Action of June 13, 2007

15-16. (Cancelled)

17. (Currently Amended) The process according to claim 11, wherein the first solvent is

acetone and wherein and the second solvent [[is]] are present in combination (i) which is acetone

and diisopropyl ether.

18. (Currently Amended) The process according to claim 11, wherein the first solvent is

dichloromethane and wherein and the second solvent [[is]] are present in combination (ii) which

is dichloromethane and diisopropyl ether.

19. (Currently Amended) The process according to claim 11, wherein the first solvent is

dichloromethane and wherein and the second solvent [[is]] are present in combination (iv) which

is dichloromethane and ethyl acetate.

20. (Previously Presented) The process according to claim 11, wherein said first solvent

is present in an amount not greater than 37 ml per gram of clopidogrel base.

21. (Previously Presented) The process according to claim 11, wherein said first solvent

is present in an amount of between 31 and 37 ml per gram of clopidogrel base.

Docket No.: 1060-0163PUS1